Alpha 2.0
Login Register
» Authors » B Strober

B Strober

Explore the profile of B Strober including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 586
Followers 0
Related Specialties
Dermatology
Infectious Diseases
General Medicine
Top 10 Co-Authors
R G Langley
K Papp
K Reich
A Menter
P Foley
M Lebwohl
K A Papp
C Leonardi
R B Warren
C E M Griffiths
Published In
Br J Dermatol
J Eur Acad Dermatol Venereol
J Biol Chem
Curr Med Res Opin
J Psoriasis Psoriatic Arthritis
Affiliations
Soon will be listed here.
Recent Articles
1.
The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, et al.
J Psoriasis Psoriatic Arthritis . 2024 Sep; 7(2):71-78. PMID: 39296823
Generalized pustular psoriasis (GPP) is a rare, systemic disease characterized by persistent or recurrent flares of painful neutrophilic pustules. There is limited real-world evidence characterizing patients with GPP. To establish...
2.
Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2
Armstrong A, Eyerich K, Conrad C, Zhu Y, Yang Y, Miller M, et al.
J Eur Acad Dermatol Venereol . 2023 Jul; 37(12):e1375-e1379. PMID: 37415560
No abstract available.
3.
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, et al.
J Eur Acad Dermatol Venereol . 2023 Jun; 37(10):2047-2055. PMID: 37319109
Background: Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at Weeks 12 and 16 in phase 3 studies, with a manageable safety profile. Patient-reported outcomes with long-term abrocitinib...
4.
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance
Reich K, Gordon K, Strober B, Langley R, Miller M, Yang Y, et al.
J Eur Acad Dermatol Venereol . 2022 Aug; 36(12):2393-2400. PMID: 35920762
Background: Psoriasis is a chronic immune-mediated inflammatory skin disease that often leads to a diminished quality of life. Goals of treating patients with psoriasis have shifted with more focus on...
5.
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis
Gooderham M, Pinter A, Ferris L, Warren R, Zhan T, Zeng J, et al.
J Eur Acad Dermatol Venereol . 2022 Feb; 36(6):855-865. PMID: 35174556
Background: Risankizumab has demonstrated durable, high rates of efficacy in patients with moderate-to-severe plaque psoriasis as assessed by the achievement of relative Psoriasis Area and Severity Index (PASI) improvement and ...
6.
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
Reich K, Mrowietz U, Menter A, Griffiths C, Bagel J, Strober B, et al.
J Eur Acad Dermatol Venereol . 2021 Jul; 35(12):2409-2414. PMID: 34255891
Background: Treating to absolute treatment targets rather than relative measures such as Psoriasis Area and Severity Index (PASI)-75 is emerging as an important clinical concept included in psoriasis guidelines and...
7.
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
Van Voorhees A, Stein Gold L, Lebwohl M, Strober B, Sofen H, Papp K, et al.
Br J Dermatol . 2021 Mar; 185(4):840-842. PMID: 33763874
No abstract available.
8.
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies
Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, et al.
J Eur Acad Dermatol Venereol . 2020 Apr; 34(12):2830-2838. PMID: 32320088
Background: Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin-23 through binding the p19 subunit. In Phase 3 trials, risankizumab demonstrated superior efficacy compared with adalimumab and ustekinumab...
9.
Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis
Leonardi C, Papp K, Strober B, Thaci D, Warren R, Tyring S, et al.
Br J Dermatol . 2018 Sep; 180(1):76-85. PMID: 30169904
Background: Adalimumab (Humira , AbbVie Inc., North Chicago, IL, U.S.A.) is a fully human monoclonal antibody specific for tumour necrosis factor-α that is approved to treat adults with moderate-to-severe chronic...
10.
Systematic review of the real-world evidence of adalimumab safety in psoriasis registries
Strober B, Crowley J, Langley R, Gordon K, Menter A, Leonardi C, et al.
J Eur Acad Dermatol Venereol . 2018 Aug; 32(12):2126-2133. PMID: 30067882
Long-term safety of adalimumab in psoriasis clinical studies has been established. The objective of this research was to review real-world evidence of adalimumab safety from registries of adult patients with...